Hospital
Bluefield Hospital Company LLC
Bluefield Hospital Company LLC was paid $12.45M by Medicaid between Jan 2018 and Jul 2020, across 207 billing codes. Its largest line is J3490, Unclassified drugs — 14% of everything it billed.
33Billing provider infoBLUEFIELD HOSPITAL COMPANY LLC
BLUEFIELD, WV 24701
BLUEFIELD, WV 24701
33aNPI1477869295assigned 08/31/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.45M
24GClaims322,306
24DCodes billed207
24AFirst – last monthJan 2018 – Jul 2020
Compared with peers
Next to other General Acute Care Hospital providers in West Virginia
Rank by total paid#16 of 26
Median peer was paid$18.33M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 142,804 | $6.16M | |
| 2019 | 108,286 | $4.35M | |
| 2020 | 71,216 | $1.94M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J3490 | Unclassified drugs | 14% | 31,425 | 10,386 | $1.69M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.0% | 14,419 | 11,172 | $1.12M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.0% | 4,046 | 3,111 | $990K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.8% | 7,526 | 6,089 | $841K |
| 36415 | Collection of venous blood by venipuncture | 2.6% | 21,650 | 15,297 | $328K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.3% | 2,184 | 1,763 | $284K |
| 80053 | Comprehensive metabolic panel | 2.3% | 17,084 | 12,780 | $280K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 17,889 | 12,956 | $276K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 3,751 | 2,738 | $245K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 7,171 | 5,184 | $230K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 3,313 | 2,266 | $223K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.8% | 1,833 | 1,446 | $222K |
195 more codes
| J3010 | Injection, fentanyl citrate, 0.1 mg | 1.5% | 2,773 | $192K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 2,732 | $171K |
| G0378 | Hospital observation service, per hour | 1.3% | 930 | $164K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 1.3% | 2,337 | $164K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 2,181 | $161K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 3,618 | $155K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 6,233 | $135K |
| 71045 | Radiologic examination, chest; single view | 1.0% | 4,853 | $131K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1.0% | 4,022 | $127K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,557 | $123K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,924 | $111K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,269 | $110K |
| 85027 | <1% | 3,516 | $109K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,455 | $108K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,138 | $107K |
| 85610 | <1% | 2,589 | $105K | |
| 87400 | <1% | 4,247 | $105K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,219 | $101K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,519 | $92K |
| 84484 | <1% | 5,956 | $92K | |
| 81003 | <1% | 6,945 | $91K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,298 | $90K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 644 | $89K |
| 85730 | <1% | 1,708 | $86K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,207 | $86K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 434 | $83K |
| C1769 | Guide wire | <1% | 553 | $77K |
| 93458 | <1% | 109 | $76K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 891 | $75K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 984 | $71K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,551 | $66K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,981 | $63K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 854 | $62K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,268 | $61K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,298 | $59K |
| 83690 | <1% | 3,487 | $58K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,024 | $56K |
| 82553 | <1% | 3,303 | $54K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,096 | $53K |
| 87040 | <1% | 2,194 | $53K | |
| 82550 | <1% | 3,840 | $49K | |
| 83735 | <1% | 3,461 | $49K | |
| 83880 | <1% | 1,726 | $48K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 395 | $47K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,092 | $47K |
| 82805 | <1% | 1,325 | $43K | |
| 86140 | <1% | 3,048 | $42K | |
| 87186 | <1% | 1,720 | $36K | |
| 72110 | <1% | 962 | $35K | |
| 81001 | <1% | 3,553 | $34K | |
| 80061 | Lipid panel | <1% | 2,266 | $34K |
| 83605 | <1% | 1,584 | $33K | |
| 82962 | <1% | 3,422 | $33K | |
| 82150 | <1% | 1,599 | $32K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,067 | $32K |
| 93971 | <1% | 527 | $32K | |
| 96376 | <1% | 962 | $30K | |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | <1% | 202 | $30K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 396 | $29K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 456 | $29K |
| 84703 | <1% | 1,835 | $28K | |
| 87070 | <1% | 1,198 | $28K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,371 | $26K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 340 | $26K |
| 87205 | <1% | 1,230 | $26K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 596 | $23K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,070 | $22K |
| 99152 | <1% | 225 | $22K | |
| 87077 | <1% | 643 | $22K | |
| 93017 | <1% | 153 | $21K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,784 | $21K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 926 | $20K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 998 | $20K |
| 73562 | <1% | 774 | $20K | |
| J0592 | Injection, buprenorphine hydrochloride, 0.1 mg | <1% | 572 | $19K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 583 | $19K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 65 | $18K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 392 | $18K |
| 36600 | <1% | 1,292 | $18K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 374 | $17K |
| 85379 | <1% | 771 | $17K | |
| 84702 | <1% | 997 | $17K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 792 | $17K |
| 73030 | <1% | 821 | $17K | |
| 74019 | <1% | 546 | $16K | |
| 87807 | <1% | 981 | $16K | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 212 | $16K |
| 74018 | <1% | 709 | $15K | |
| 85007 | <1% | 513 | $14K | |
| 81025 | <1% | 786 | $14K | |
| 87088 | <1% | 1,007 | $13K | |
| 73630 | <1% | 710 | $13K | |
| 64483 | <1% | 47 | $12K | |
| 73610 | <1% | 501 | $11K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 372 | $11K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 374 | $11K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 373 | $11K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 146 | $11K |
| 73130 | <1% | 406 | $10K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 426 | $10K |
| 96367 | <1% | 314 | $10K | |
| 73502 | <1% | 443 | $10K | |
| 86900 | <1% | 713 | $10K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 629 | $10K |
| 86901 | <1% | 712 | $9K | |
| 82607 | <1% | 484 | $9K | |
| 85018 | <1% | 801 | $9K | |
| 85014 | <1% | 753 | $9K | |
| 90715 | <1% | 232 | $8K | |
| 86850 | <1% | 446 | $8K | |
| 83721 | <1% | 707 | $8K | |
| 87081 | <1% | 849 | $8K | |
| 84439 | <1% | 595 | $8K | |
| 72050 | <1% | 186 | $8K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 240 | $7K |
| 72070 | <1% | 114 | $7K | |
| 83540 | <1% | 331 | $6K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 33 | $6K |
| 83550 | <1% | 270 | $6K | |
| 82950 | <1% | 605 | $6K | |
| 70486 | <1% | 63 | $6K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 73 | $6K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 69 | $5K |
| 73110 | <1% | 198 | $5K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 340 | $5K |
| 73590 | <1% | 88 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 378 | $5K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 91 | $5K |
| 73560 | <1% | 314 | $5K | |
| 86592 | <1% | 581 | $5K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 347 | $5K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 130 | $4K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $4K |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 69 | $4K |
| 84550 | <1% | 372 | $4K | |
| C1780 | Lens, intraocular (new technology) | <1% | 81 | $4K |
| 36416 | <1% | 851 | $3K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 60 | $3K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 27 | $3K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 141 | $3K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13 | $3K |
| 85652 | <1% | 267 | $3K | |
| 84436 | <1% | 236 | $3K | |
| 87210 | <1% | 194 | $2K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 42 | $2K |
| 80074 | <1% | 61 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 18 | $2K |
| 82272 | <1% | 123 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 140 | $2K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 15 | $2K |
| 82140 | <1% | 19 | $2K | |
| 82746 | <1% | 43 | $2K | |
| 73100 | <1% | 76 | $1K | |
| 82247 | <1% | 287 | $1K | |
| 88304 | <1% | 107 | $1K | |
| 83655 | <1% | 155 | $1K | |
| 82043 | <1% | 140 | $1K | |
| 86308 | <1% | 164 | $1K | |
| 82728 | <1% | 90 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 195 | $1K |
| 76536 | <1% | 22 | $1K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 131 | $992.76 |
| 59025 | Fetal non-stress test | <1% | 52 | $970.11 |
| 97161 | <1% | 27 | $925.39 | |
| 73080 | <1% | 55 | $902.14 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 36 | $876.64 |
| 87806 | <1% | 33 | $844.44 | |
| 88312 | <1% | 19 | $823.52 | |
| 76775 | <1% | 14 | $808.46 | |
| 73090 | <1% | 49 | $727.45 | |
| 71250 | <1% | 34 | $706.29 | |
| 84481 | <1% | 33 | $577.45 | |
| 51702 | <1% | 29 | $574.66 | |
| 73140 | <1% | 20 | $535.53 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 20 | $522.49 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 52 | $495.10 |
| 72170 | <1% | 29 | $416.78 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 229 | $373.69 |
| 82570 | <1% | 44 | $360.79 | |
| 82009 | <1% | 28 | $261.96 | |
| 96368 | <1% | 26 | $253.40 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 13 | $250.32 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 49 | $237.86 |
| 86885 | <1% | 37 | $204.22 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 49 | $202.50 |
| 80076 | <1% | 24 | $194.79 | |
| 82248 | <1% | 42 | $174.35 | |
| 87075 | <1% | 16 | $150.60 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 60 | $145.12 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 91 | $96.03 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 45 | $40.97 |
| 82565 | <1% | 20 | $40.96 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 13 | $35.02 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 17 | $15.16 |
| A9270 | Non-covered item or service | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR /DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.